Avid Bioservices Inc (CDMO)

[biopharm]

How many patents exist that infringe upon PS Targeting patents are out there that Avid CDMO or Oncologie do nothing about?...as it becomes increasingly clear that Biomarkers derived out of PS Targeting are worth Billions ...which is crucial why Eli Lilly just went public re: PS Targeting Sept 10 to Nov 19 to just last week that PS Targeting Biomarkers were given the 100% ok to remain hidden to block away from other BPs that have not gained a full understanding of the protein pathway changes DUE to PS Targeting

Well...Avid CDMO has a contract that was never 100% released to public but we do know Avid CDMO picks up all manufacturing and about 15% net sales

Send in the complaints to FDA SEC and one must send to FBI because most times FDA and SEC don't push unless they get pushed ...and to DOJ because FBI needs to be on alert as well ...and DHHS giving patents to Ridgeback Capital affiliate Ridgeback Biotherapeutics (mab114 etc) Wayne Holman (ties Steve Cohen etc)

______

As for Bio-Rad that supplies Bavituximab / PS Targeting antibodies ...would it not raise flags to Oncologie Inc or Avid Bioservices BOD and if not....why not?

______

Merck & MorphoSys AG

https://www.morphosys.com/media-investors/media-center/morphosys-and-merck-serono-enter-strategic-immuno-oncology

_____

Bio-Rad (Norman David Schwartz sin of Alice Schwartz ) has many subsidiaries such as RainDance (liquid biopsies ) in Billerica MA / GnuBio in Cambridge MA / MorphoSys US ( with big ties to MorphoSys AG and Merck ) and the list goes on .....

Would it not be a conflict of interest where the Avid CDMO allows the selling of Bavituximab via Bio-Rad to self serving Merckly networks and not one question arises from our BODs at Avid and as for Oncologie Inc ....who knows who they work for as it certainly now should raise major red flags that Merck is their way to advance the IP assets .....

I guess we could always ask Ronald T Aimes at Emergent Biosolutions ( split off into two with Aptevo ) and PS Targeting based patents as Aimes worked for Peregrine etc etc and MidCap Financial on some of their patents as well .....

Maybe we should start demanding answers from Scottish Development International players involved ...

I
___

February 05, 2019 / 10:01 pm, CET

Planegg/Munich, Germany, February 5, 2019


MorphoSys Announces Appointment of David Trexler as President and Member of the Board of Directors of MorphoSys US Inc.

...
...
Mr. Trexler has built his career in leadership positions for branded pharmaceuticals in marketing, sales, business development and general management. He joins MorphoSys from EMD Serono, a business of Merck KGaA, Darmstadt, Germany, where he held positions of increasing seniority including most recently positions as Global Brand Lead, Bavencio and Senior Vice President US Oncology Commercial. At EMD Serono, he was responsible for building Merck KGaA's first commercial oncology footprint in the U.S. and for the successful launch of Bavencio (avelumab) for metastatic Merkel cell carcinoma (mMCC).